Scientific Advisory Board

Sooma’s Scientific Advisory Board (SAB) is comprised of four board-certified and internationally recognized scientists with significant experience in the areas of non-invasive brain stimulation, psychiatry, behavioral sciences, neurology, neuropsychiatric, and biological psychiatry. More details about the SAB members below.

The Scientific Advisory Board will provide scientific guidance and help to design clinical studies to support the development of Sooma’s neuromodulation treatments and to reach new regulatory milestones.

Sooma has established this world-class Scientific Advisory board to secure top qualified guidance as we explore opportunities to develop our solution towards personalized therapies. The SAB also provides Sooma with access to relevant networks and partners across the world.

Professor Mark George

Professor Mark George received his medical degree from the Medical University of South Carolina in Charleston in 1985, where he continued with dual residencies in both neurology and psychiatry. He is board-certified in both areas. Following his residency training, he worked for one year (1990-91) as a Visiting Research Fellow in the Raymond Way Neuropsychiatry Research Group at the Institute of Neurology, Queen Square, London, England. He then moved to Washington, DC, working with Dr. Robert Post in the Biological Psychiatry Branch of the Intramural National Institute of Mental Health (NIMH).  During his 4 years at NIMH, he was one of the first to use functional imaging (particularly oxygen PET) and discovered that specific brain regions change activity during normal emotions. This led to work using imaging to understand brain changes that occur in depression and mania. This imaging work directly led to his pioneering use of a non-invasive brain stimulation method, transcranial magnetic stimulation (TMS), as a probe of neuronal circuits regulating mood, and to clinical trials using TMS as an antidepressant. In 1993 while at the NIMH, he discovered that daily prefrontal rTMS over several weeks could treat depression, and ever since he has worked to grow the science of TMS, both in terms of how it works in the brain, and in critically evaluating its therapeutic applications, especially in the area of treating depression.


In June 1998 at MUSC, he also helped pioneer another new treatment for resistant depression, vagus nerve stimulation (VNS). This was FDA-approved in 2006. Most recently he was the PI on an international trial that resulted in TMS being FDA approved to help with smoking cessation.

Dr. George is thus a world expert in brain imaging and brain stimulation, particularly combining the two. Clinically he is an expert on depression and several other neuropsychiatric disorders. He is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has served as the chief editor for 13 years now and this journal is the top in its field.

He has been continuously funded by NIH and other funding agencies since his fellowships. He has received both a NARSAD Young Investigator and Independent Investigator Award to pursue TMS research in depression. He has received numerous international awards including the NARSAD Klerman Award (2000), NARSAD Falcone Award (2008), and the Lifetime Achievement Award (2007) given by the World Federation of Societies of Biological Psychiatry (WFSBP). He is on several editorial review boards and NIH study sections, has published over 500 scientific articles or book chapters, and has written or edited 6 books.

Assistant Professor Nolan Williams

Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioural Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in clinical neuroscience and is triple board-certified in general neurology, general psychiatry, as well as behavioral neurology, and neuropsychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies under Mark George, MD. The themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. He has published papers in high-impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. Dr. Williams received the National Institute of Mental Health Biobehavioral Research Award for Innovative New Scientists in 2020.

Professor Frank Padberg

Dr. Padberg is Professor of Psychiatry and Psychotherapy and Director of the Center for Non-invasive Brain Stimulation Munich Augsburg (CNBSMA) and the Section of Psychosomatic Medicine and Psychotherapy at the Ludwig-Maximilians University Hospital Munich, Dept. of Psychiatry. His research focus as a clinician scientist is on the development of novel, safe and effective non-pharmacological interventions for difficult-to-treat affective disorders, i.e. therapy-resistant or chronic depression or depression with significant psychiatric co-morbidities (e.g. borderline personality disorder, posttraumatic disorder – complex affective disorders).

Within two research groups, he and his co-workers are currently following different lines of research to achieve this overarching goal: 1) understanding the complexity of affective disorders by characterizing clinical, psychological (e.g. trauma, resilience, attachment, loneliness) and neurobiological features (e.g. oxytocin, HPA regulation) in affective disorders, 2) investigating mechanisms of action in psychotherapy (e.g. of Cognitive Behavioral Analysis System of Psychotherapy – CBASP), and 3) developing non-invasive brain stimulation (NIBS) methods (e.g. repetitive transcranial magnetic stimulation – rTMS, transcranial direct current stimulation – tDCS) to provide safe and effective therapeutic interventions.

The third research track is most advanced and has been implemented as a translational research program funded by the Ministry of Education and Research (BMBF, since 2015 German Center for Brain Stimulation – GCBS). But already as a young resident in 1997, Dr. Padberg has got interested in rTMS and published a first small pilot trial on major depressive disorder (MDD) in 1999. The vision of non-invasively stimulating cortical brain regions for providing effective therapy in MDD and other psychiatric disorders has accompanied his work, and nowadays turned to clinical practice. Today, NIBS represents a rapidly developing field of innovation in mental health research. Dr. Padberg widely contributed to this field (e.g. see google scholar: h-index: 62, i10-index: 172, 19972 citations).

Dr. Daniel Blumberger

Dr. Daniel Blumberger is the scientific director of the Temerty Centre for Therapeutic Brain Intervention, co-chief of General Adult Psychiatry and Health Systems, and a senior scientist at the Centre for Addiction and Mental Health (CAMH). He additionally holds the Temerty Chair in Therapeutic Brain Intervention at CAMH. He is a subspecialist in geriatric psychiatry and a professor in the Department of Psychiatry in the Temerty Faculty of Medicine at the University of Toronto and a full member of the Institute of Medical Sciences.

Dr. Blumberger’s research focuses on the use of interventional psychiatry approaches with a focus on brain stimulation therapies for refractory psychiatric disorders. His main research focuses on clinical intervention trials of novel treatments and understanding the neurobiology of treatment-resistant depression across the lifespan. His research has been funded by the Canadian Institutes of Health Research, National Institute of Mental Health (US), Brain Canada, Weston Brain Institute, Wellcome Trust, Brain and Behavior Research Foundation, and Patient- Centered Outcomes Research Institute. He is the principal investigator or co-investigator on multiple clinical trials using different brain stimulation modalities and novel drug approaches including: electroconvulsive therapy (ECT), ketamine, magnetic seizure therapy (MST), psilocybin, repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).


View Dr. Blumberger’s publications on PubMed


In addition to the Scientific Advisory Board, we also have a wide network of clinical advisors to help us understand the best clinical practices for our therapies.